L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Privately held pharmaceutical company dedicated to R&D of novel compounds for the treatment of cancers and viral diseases. Validated assays to test drugs, disinfectants and devices against COVID-19 offered by a highly qualified team.
Sassari, Sardinia, Italy
Send a message
ViroStatics expands its respiratory viruses neutralization analysis to aerosol forms.
For more information, please contact our CSO Davide De Forni at email@example.com
ViroStatics among the best Italy-based Pharmaceutical companies.
Companies were selected across the size spectrum from cutting edge startups to established brands.
Startups and companies listed were chosen for exceptional performance in one of these categories:
Biological Safety Level 3 laboratory to test anti-SARS-CoV-2 products.
If you are interested in testing your drugs (or natural substances), detergents/disinfectants, and devices (e.g. UV lamps), please contact Davide De Forni, PhD at firstname.lastname@example.org
Few Laboratories worldwide can offer a validated and robust testing of drugs and devices against SARS-CoV-2.
Our Team has the EXPERTISE to test drugs or devices for SARS-CoV-2 inactivation and the capability to work in a BSL3 AREA as required to manipulate dangerous viruses.
At ViroStatics and RIGHT (Research Institute for Genetic and Human Therapy) we are in the position to test in vitro any antiviral (drug, biologic, etc.) against new coronavirus, thanks to our extensive antivirals expertise and the capability to work in a BSL3 area as required to manipulate new coronavirus according to guidelines (https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html).
If you are interested to have any compound tested by us, please contact ViroStatics CSO, Davide De Forni, at email@example.com
ViroStatics scientists have >30 years experience testing antivirals, including double and triple drug combinations, both in the laboratory and in the clinics, leading to the description of the first functional cure of an HIV infected patient (the Berlin Patient, New England Journal of Medicine, 1999).